Having assessed the novel anti-inflammatory and antithrombotic effects of AnxA1 on platelets isolated from AnxA1-treated mice after cerebral I/RI, we wanted to address in vivo whether AnxA1 administration might also be effective in reducing the prothrombotic events that may ultimately lead to stroke and reducing the effect of subsequent thrombotic events after stroke. The gene discussed is ANXA1; the disease is stroke disorder.